Moberg Pharma AB (publ) (MOB.ST)
SEK 11.28
(10.37%)
SEK 11.28
(10.37%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -27.46 Million SEK | -33.85% |
| 2022 | -20.51 Million SEK | -3.99% |
| 2021 | -19.73 Million SEK | 9.01% |
| 2020 | -21.68 Million SEK | 0.0% |
| 2018 | 64.81 Million SEK | 26.91% |
| 2017 | 51.07 Million SEK | -17.85% |
| 2016 | 62.17 Million SEK | 76.71% |
| 2015 | 35.18 Million SEK | 104.24% |
| 2014 | 17.22 Million SEK | 222.57% |
| 2013 | -14.05 Million SEK | -211.6% |
| 2012 | 12.59 Million SEK | 265.75% |
| 2011 | -7.59 Million SEK | 74.77% |
| 2010 | -30.11 Million SEK | -24.07% |
| 2009 | -24.27 Million SEK | 33.85% |
| 2008 | -36.7 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.43 Million SEK | 31.21% |
| 2024 Q1 | -7.89 Million SEK | 7.02% |
| 2023 Q3 | -7.26 Million SEK | -37.16% |
| 2023 Q1 | -6.67 Million SEK | -45.1% |
| 2023 FY | -28.51 Million SEK | -38.99% |
| 2023 Q2 | -5.29 Million SEK | 20.67% |
| 2023 Q4 | -8.49 Million SEK | -16.95% |
| 2022 Q2 | -4.94 Million SEK | 8.84% |
| 2022 Q1 | -5.42 Million SEK | -10.86% |
| 2022 FY | -20.51 Million SEK | -3.99% |
| 2022 Q3 | -5.26 Million SEK | -6.52% |
| 2022 Q4 | -4.59 Million SEK | 12.63% |
| 2021 FY | -19.73 Million SEK | 9.01% |
| 2021 Q4 | -4.89 Million SEK | -5.09% |
| 2021 Q1 | -6.06 Million SEK | -1.66% |
| 2021 Q2 | -4.11 Million SEK | 32.12% |
| 2021 Q3 | -4.65 Million SEK | -12.96% |
| 2020 FY | -21.68 Million SEK | 0.0% |
| 2020 Q1 | -4.21 Million SEK | 12.14% |
| 2020 Q4 | -5.96 Million SEK | -15.01% |
| 2020 Q2 | -6.31 Million SEK | -49.82% |
| 2020 Q3 | -5.19 Million SEK | 17.78% |
| 2019 Q4 | -4.79 Million SEK | -111.48% |
| 2019 Q1 | 4.95 Million SEK | -78.03% |
| 2019 Q3 | 41.75 Million SEK | 555.32% |
| 2019 Q2 | -9.17 Million SEK | -285.2% |
| 2018 Q2 | 16.25 Million SEK | 29.8% |
| 2018 FY | 64.81 Million SEK | 26.91% |
| 2018 Q4 | 22.53 Million SEK | 66.82% |
| 2018 Q3 | 13.51 Million SEK | -16.87% |
| 2018 Q1 | 12.52 Million SEK | -28.77% |
| 2017 Q3 | 26.55 Million SEK | 66292.5% |
| 2017 FY | 51.07 Million SEK | -17.85% |
| 2017 Q1 | 6.9 Million SEK | -2.22% |
| 2017 Q4 | 17.57 Million SEK | -33.82% |
| 2017 Q2 | 40 Thousand SEK | -99.42% |
| 2016 FY | 62.17 Million SEK | 76.71% |
| 2016 Q1 | 503 Thousand SEK | -52.86% |
| 2016 Q2 | 31.24 Million SEK | 6112.13% |
| 2016 Q3 | 23.36 Million SEK | -25.23% |
| 2016 Q4 | 7.05 Million SEK | -69.79% |
| 2015 FY | 35.18 Million SEK | 104.24% |
| 2015 Q1 | 14.89 Million SEK | 962.7% |
| 2015 Q3 | 10.93 Million SEK | 32.05% |
| 2015 Q2 | 8.28 Million SEK | -44.41% |
| 2015 Q4 | 1.06 Million SEK | -90.24% |
| 2014 Q4 | 1.4 Million SEK | -73.52% |
| 2014 Q2 | 4.83 Million SEK | -15.17% |
| 2014 Q1 | 5.69 Million SEK | 589.71% |
| 2014 FY | 17.22 Million SEK | 222.57% |
| 2014 Q3 | 5.29 Million SEK | 9.56% |
| 2013 FY | -14.05 Million SEK | -211.6% |
| 2013 Q4 | 826 Thousand SEK | 118.07% |
| 2013 Q3 | -4.57 Million SEK | 30.6% |
| 2013 Q2 | -6.58 Million SEK | -77.1% |
| 2013 Q1 | -3.72 Million SEK | -458.56% |
| 2012 Q2 | 1.36 Million SEK | -82.8% |
| 2012 Q1 | 7.93 Million SEK | 109.67% |
| 2012 FY | 12.59 Million SEK | 265.75% |
| 2012 Q4 | -666 Thousand SEK | -116.84% |
| 2012 Q3 | 3.95 Million SEK | 189.82% |
| 2011 Q2 | -9.66 Million SEK | -45.11% |
| 2011 Q4 | 3.78 Million SEK | -23.3% |
| 2011 Q3 | 4.93 Million SEK | 151.09% |
| 2011 Q1 | -6.65 Million SEK | 25.7% |
| 2011 FY | -7.59 Million SEK | 74.77% |
| 2010 Q1 | -4.7 Million SEK | 0.0% |
| 2010 FY | -30.11 Million SEK | -24.07% |
| 2010 Q3 | -8.4 Million SEK | -4.54% |
| 2010 Q4 | -8.96 Million SEK | -6.57% |
| 2010 Q2 | -8.04 Million SEK | -70.91% |
| 2009 FY | -24.27 Million SEK | 33.85% |
| 2008 FY | -36.7 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | -107.284% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | 28.224% |
| BioGaia AB (publ) | 440.9 Million SEK | 106.229% |
| Enzymatica AB (publ) | -48.06 Million SEK | 42.859% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | 34.359% |
| Gabather AB (publ) | -9.47 Million SEK | -189.878% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | -87.078% |
| Nanexa AB (publ) | -76.62 Million SEK | 64.159% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | -95.077% |
| ODI Pharma AB | -1.34 Million SEK | -1946.972% |
| Orexo AB (publ) | -109.5 Million SEK | 74.92% |
| Probi AB (publ) | 11.32 Million SEK | 342.606% |
| Swedencare AB (publ) | 173.2 Million SEK | 115.856% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 100.59% |
| Toleranzia AB | -7.89 Million SEK | -248.029% |
| Vivesto AB | -356.71 Million SEK | 92.301% |